Completed

4RTNIObservational Longitudinal Study of Magnetic Resonance Imaging, Specimen Biomarkers, and Clinical Progression in Progressive Supranuclear Palsy and Corticobasal Degeneration

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being collected

Data Collection

Collected from today forward - Prospective
OtherDNA Samples
Who is being recruted

Basal Ganglia Diseases+20

+ Mental Disorders

+ Brain Diseases

From 45 to 90 Years
+5 Eligibility Criteria
See all eligibility criteria
How is the trial designed

Cohort

Tracking disease incidence in order to identify risk factors and understand disease progression over time.
Observational
Study Start: January 2011
See protocol details

Summary

Principal SponsorUniversity of California, San Francisco
Last updated: May 8, 2025
Sourced from a government-validated database.Claim as a partner

Study start date: January 10, 2011

Actual date on which the first participant was enrolled.

The purpose of this study is to evaluate several different tests, including brain imaging, eye movement testing, body fluid samples, measurements of memory and other thinking abilities, and measures of functional independence in the hope that this information can be used to guide diagnosis and treatment of PSP and CBD in the future. Recent advances in our understanding of the biological causes of these diseases offer hope for new treatments. As such treatments are developed, sensitive and specific biological measurements (biomarkers) will be needed to provide precise and direct measures of the state of the brain, which will improve the statistical power of clinical trials. Brain imaging with Magnetic Resonance Imaging (MRI) has previously been used to measure disease-related changes in the brain. The goal of this study is to identify the best methods of analysis (including eye movements, imaging, and behavioral measures) for tracking PSP and CBD over time. In addition, certain biomarkers in the blood and cerebrospinal fluid might also be useful for following these diseases over time. This study will examine the value of blood and CSF biomarkers relative to brain imaging and functional measures.

NCT01804452
Principal SponsorUniversity of California, San Francisco
Last updated: May 8, 2025
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

110 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Cohort

These studies follow a group of individuals with common characteristics (such as a condition or birth year) over a specific period to study health outcomes or exposures.

Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

From 45 to 90 Years

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Basal Ganglia DiseasesMental DisordersBrain DiseasesCentral Nervous System DiseasesCranial Nerve DiseasesDementiaEye DiseasesMovement DisordersNervous System DiseasesNeurologic ManifestationsOphthalmoplegiaParalysisSigns and SymptomsPathological Conditions, Signs and SymptomsOcular Motility DisordersNeurodegenerative DiseasesNeurocognitive DisordersTauopathiesFrontotemporal Lobar DegenerationFrontotemporal DementiaCorticobasal DegenerationSupranuclear Palsy, ProgressivePick Disease of the Brain

Criteria

3 inclusion criteria required to participate
Clinical diagnosis of Progressive Supranuclear Palsy or Corticobasal Degeneration
Must have a reliable study partner who has frequent contact with the subject
Willing and able to undergo testing procedures
2 exclusion criteria prevent from participating
Presence of pacemakers, aneurysm clips, artificial heart valves, ear implants, metal fragments or foreign objects in the eyes, skin or body
Significant neurological disease other than PSP or CBD

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.
Treatment Groups
Study Objectives

One single intervention group is designated in this study

This study does not include a placebo group 

Treatment Groups

Study Objectives

Primary Objectives

Secondary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 2 locations

University of California, San Francisco

San Francisco, United StatesOpen University of California, San Francisco in Google Maps

John Hopkins University

Baltimore, United States
Completed2 Study Centers